Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Sep 20;36(1):109-110.
doi: 10.1080/08998280.2022.2123666. eCollection 2023.

Opsoclonus myoclonus and ataxia syndrome with supraventricular tachycardia

Sydney Garner  1 , Alec Giakas  1 , Katherine Holder  2 , Bernardo Galvan  2 , Hollie Edwards  3
Affiliations
Case Reports

Opsoclonus myoclonus and ataxia syndrome with supraventricular tachycardia

Sydney Garner et al. Proc (Bayl Univ Med Cent). .

Abstract

Pediatric opsoclonus-myoclonus and ataxia syndrome (OMAS) is a neurologic disorder characterized by disturbances in eye movement, muscle jerks, ataxia, sleep, and mood. In approximately 50% of cases, it is a paraneoplastic syndrome associated with a neuroblastoma. In the remaining cases, it is believed that the tumor is occult, has involuted, or there is a preceding immune-stimulating event. While neuroblastomas can be associated with other paraneoplastic syndromes, supraventricular tachycardia (SVT) is rarely reported in the literature, and to our knowledge, this is the first case of SVT secondary to idiopathic OMAS. Confounding treatment toxicity, including intravenous immunoglobulin and other immunomodulatory drugs, should be screened for possible cardiovascular side effects in OMAS patients. The development of cardiac arrhythmias during OMAS treatment is not a contraindication to therapy. In these patients, arrhythmias should be controlled with vagal maneuvers or antiarrhythmics as needed while OMAS treatment is completed.

Keywords: Ataxia; myoclonus; opsoclonus; supraventricular tachycardia.

PubMed Disclaimer

References

    1. Pranzatelli MR, Tate ED, McGee NR.. Demographic, clinical, and immunologic features of 389 children with opsoclonus-myoclonus syndrome: a cross-sectional study. Front Neurol. 2017;8:468. doi:10.3389/fneur.2017.00468. - DOI - PMC - PubMed
    1. Pike M. Opsoclonus–myoclonus syndrome. In: Dulac O, Lassonde M, Sarnat HB, eds. Handbook of Clinical Neurology. Amsterdam, Netherlands: Elsevier; 2013:1209–1211. doi:10.1016/B978-0-444-52910-7.00042-8. - DOI - PubMed
    1. Storz C, Bares R, Ebinger M, Handgretinger R, Tsiflikas I, Schäfer JF.. Diagnostic value of whole-body MRI in opsoclonus-myoclonus syndrome: a clinical case series (3 case reports). BMC Med Imaging. 2019;19(1):70. doi:10.1186/s12880-019-0372-y. - DOI - PMC - PubMed
    1. Zhang YT, Feng LH, Zhang Z, Zhong XD, Chang J.. Different kinds of paraneoplastic syndromes in childhood neuroblastoma. Iran J Pediatr. 2015;25(1):e266. doi:10.5812/ijp.266. - DOI - PMC - PubMed
    1. Tufekci S, Coban A, Bor M, Yasa B, Nisli K, Ince Z.. Cardiac rhythm abnormalities during intravenous immunoglobulin G (IVIG) infusion in two newborn infants: coincidence or association? Clin Case Rep. 2015;3(9):731–734. doi:10.1002/ccr3.329. - DOI - PMC - PubMed

Publication types

LinkOut - more resources